Movement Alert｜Merck Falls 3.02% in Regular Trading, Trial Progress Overshadowed by Cautious Pre-Earnings Expectations

Market Focus10-27 00:42

On October 27, Merck fell 3.02% in Regular Trading, trading at $140.94/share, with turnover of $646 million.

The immediate backdrop was a mixed market read on new oncology data: Merck reported positive phase 3 progress in advanced or recurrent endometrial cancer, but investors remained cautious ahead of its upcoming earnings release.

Keytruda monotherapy reduced the risk of disease progression or death by 43% versus platinum-doublet chemotherapy, with median progression-free survival of 38.2 months versus 8.4 months. Separately, sacituzumab tirumotecan reduced the risk of death by 32% and the risk of progression or death by 41% versus physician’s choice treatment, while also improving objective response rate.

Even with those clinical updates, consensus expectations point to limited near-term earnings momentum. Market estimates indicate quarterly revenue of $17.282 billion, up 1.88% year over year, while adjusted EPS is expected at $2.09, down 11.01%, and EBIT at $6.420 billion, down 7.48%, suggesting margin recovery still needs clearer confirmation.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment